Ror2 Signaling and Its Relevance in Breast Cancer Progression

Breast cancer is a heterogeneous disease and has been classified into five molecular subtypes based on gene expression profiles. Signaling processes linked to different breast cancer molecular subtypes and different clinical outcomes are still poorly understood. Aberrant regulation of Wnt signaling has been implicated in breast cancer progression. In particular Ror1/2 receptors and several other members of the non-canonical Wnt signaling pathway were associated with aggressive breast cancer behavior. However, Wnt signals are mediated via multiple complex pathways, and it is clinically important to determine which particular Wnt cascades, including their domains and targets, are deregulated in poor prognosis breast cancer. To investigate activation and outcome of the Ror2-dependent non-canonical Wnt signaling pathway, we overexpressed the Ror2 receptor in MCF-7 and MDA-MB231 breast cancer cells, stimulated the cells with its ligand Wnt5a, and we knocked-down Ror1 in MDA-MB231 cells. We measured the invasive capacity of perturbed cells to assess phenotypic changes, and mRNA was profiled to quantify gene expression changes. Differentially expressed genes were integrated into a literature-based non-canonical Wnt signaling network. The results were further used in the analysis of an independent dataset of breast cancer patients with metastasis-free survival annotation. Overexpression of the Ror2 receptor, stimulation with Wnt5a, as well as the combination of both perturbations enhanced invasiveness of MCF-7 cells. The expression–responsive targets of Ror2 overexpression in MCF-7 induced a Ror2/Wnt module of the non-canonical Wnt signaling pathway. These targets alter regulation of other pathways involved in cell remodeling processing and cell metabolism. Furthermore, the genes of the Ror2/Wnt module were assessed as a gene signature in patient gene expression data and showed an association with clinical outcome. In summary, results of this study indicate a role of a newly defined Ror2/Wnt module in breast cancer progression and present a link between Ror2 expression and increased cell invasiveness.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  Zena Werb,et al.  Stromal Effects on Mammary Gland Development and Breast Cancer , 2002, Science.

[3]  A. Silver,et al.  The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.

[4]  A. Kikuchi,et al.  Wnt5a: its signalling, functions and implication in diseases , 2012, Acta physiologica.

[5]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  F. Pontén,et al.  WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism , 2013, Carcinogenesis.

[7]  M. Bayerlová.  Pathway and network analyses in context of Wnt signaling in breast cancer , 2016 .

[8]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[9]  M. Askarian-Amiri,et al.  Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population , 2014, BioMed research international.

[10]  V. Yang,et al.  Wnt11 Signaling Promotes Proliferation, Transformation, and Migration of IEC6 Intestinal Epithelial Cells* , 2004, Journal of Biological Chemistry.

[11]  Jun Du,et al.  Dvl2-Dependent Activation of Daam1 and RhoA Regulates Wnt5a-Induced Breast Cancer Cell Migration , 2012, PloS one.

[12]  L. Trümper,et al.  Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. , 2004, Carcinogenesis.

[13]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[14]  Ajamete Kaykas,et al.  WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.

[15]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[16]  D. Harrington.  A class of rank test procedures for censored survival data , 1982 .

[17]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[18]  H. Wanibuchi,et al.  Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. , 2011, International journal of oncology.

[19]  Aung Ko Win,et al.  Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype , 2013, Modern Pathology.

[20]  V. Sherwood,et al.  WNT Signaling: an Emerging Mediator of Cancer Cell Metabolism? , 2014, Molecular and Cellular Biology.

[21]  T. Beißbarth,et al.  Newly Constructed Network Models of Different WNT Signaling Cascades Applied to Breast Cancer Expression Data , 2015, PloS one.

[22]  David Venet,et al.  Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..

[23]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[24]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Robinson,et al.  Small-sample estimation of negative binomial dispersion, with applications to SAGE data. , 2007, Biostatistics.

[26]  M. Dwyer,et al.  WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. , 2010, Cancer research.

[27]  Bin Zhang,et al.  Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R , 2008, Bioinform..

[28]  J. Wang-Rodriguez,et al.  ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth , 2012, PloS one.

[29]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[30]  E. Llamosas,et al.  Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling , 2015, Journal of Cancer Research and Clinical Oncology.

[31]  β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases , 2016, Clinical & Experimental Metastasis.

[32]  Yayun Liang,et al.  Estradiol down-regulates CD36 expression in human breast cancer cells. , 2004, Cancer letters.

[33]  Louise R Howe,et al.  Wnt Signaling and Breast Cancer , 2004, Cancer biology & therapy.

[34]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[36]  A. Lustig,et al.  Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration. , 2009, Blood.

[37]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[38]  P. Puigserver,et al.  PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis. , 2011, Cancer research.

[39]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[40]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[41]  Randall T. Moon,et al.  Wnt and calcium signaling: β-Catenin-independent pathways , 2005 .

[42]  T. Beißbarth,et al.  Interpreting experimental results using gene ontologies. , 2006, Methods in enzymology.

[43]  S. O'toole,et al.  Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Antara De,et al.  Wnt/Ca2+ signaling pathway: a brief overview. , 2011, Acta biochimica et biophysica Sinica.

[45]  John Quackenbush,et al.  A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.

[46]  L. Rassenti,et al.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a , 2008, Proceedings of the National Academy of Sciences.

[47]  Steve Horvath,et al.  Breast Cancer Molecular Signatures as Determined by SAGE: Correlation with Lymph Node Status , 2007, Molecular Cancer Research.

[48]  Tim Beißbarth,et al.  Comparative study on gene set and pathway topology-based enrichment methods , 2015, BMC Bioinformatics.

[49]  M. Oka,et al.  Possible involvement of Wnt11 in colorectal cancer progression , 2013, Molecular carcinogenesis.

[50]  Prasad Patil,et al.  Test set bias affects reproducibility of gene signatures , 2015, Bioinform..

[51]  C. Niehrs.  The complex world of WNT receptor signalling , 2012, Nature Reviews Molecular Cell Biology.

[52]  Susumu Goto,et al.  The KEGG resource for deciphering the genome , 2004, Nucleic Acids Res..

[53]  Amy E. Robertson,et al.  Stage of Breast Cancer Progression Influences Cellular Response to Activation of the WNT/Planar Cell Polarity Pathway , 2014, Scientific Reports.

[54]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[55]  M. Walker,et al.  Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells , 2010, Molecular Cancer.

[56]  Haifeng Zhang,et al.  Ror2 Receptor Mediates Wnt11 Ligand Signaling and Affects Convergence and Extension Movements in Zebrafish* , 2014, The Journal of Biological Chemistry.

[57]  Nobuyuki Onishi,et al.  The receptor tyrosine kinase Ror2 is involved in non‐canonical Wnt5a/JNK signalling pathway , 2003, Genes to cells : devoted to molecular & cellular mechanisms.

[58]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[59]  Holger Fröhlich,et al.  Steiner tree methods for optimal sub-network identification: an empirical study , 2012, BMC Bioinformatics.

[60]  T. Beißbarth,et al.  β-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. , 2011, Carcinogenesis.

[61]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Y. Minami,et al.  Receptor Tyrosine Kinase Ror2 Mediates Wnt5a-induced Polarized Cell Migration by Activating c-Jun N-terminal Kinase via Actin-binding Protein Filamin A* , 2008, Journal of Biological Chemistry.

[63]  A. Aman,et al.  Wnt/beta-catenin and Fgf signaling control collective cell migration by restricting chemokine receptor expression. , 2008, Developmental cell.